Skip to main content

Table 3 Mean scores before the first course of chemotherapy, changes of scores between the first and the fourth courses of responsiveness statistics in patients who perceived improved health (n = 17)

From: Responsiveness of EORTC QLQ-C30, QLQ-CR38 and FACT-C quality of life questionnaires in patients with colorectal cancer

  n Score before 1stchemother.Mean (SD a) Difference
Mean
(SD a)
Pb SRMc (CI 95%) ESd (CI 95%)
EORTC QLQ-C30:       
    Functional scalese :       
Physical function 16 67.8 (30.2) +14.9 (22.5) 0.02 0.64 (0.19;1.08) 0.48 (0.14;0.86)
Role function 16 55.9 (39.1) +21.9 (16.7) 0.03 0.60 (0.08;1.13) 0.56 (0.10;1.07)
Emotional function 17 69.6 (16.1) +16.2 (16.7) 0.003 0.84 (0.28;1.54) 1.00 (0.35;1.68)
Cognitive function 17 77.5 (20.4) +10.8 (16.6) 0.02 0.64 (0.16;1.29) 0.52 (0.14;1.09)
Social function 17 62.7 (34.1) +13.7 (38.3) 0.16 0.35 (-0.17;0.88) 0.40 (-0.20;0.89)
Global QoL/GHS 17 54.9 (20) +14.2 (14.7) 0.001 0.96 (0.38;1.67) 0.71 (-0.23;1.44)
    Symptom scalesf :       
Fatigue 16 42.8 (27.9) -16.3 (25.8) 0.02 - 0.63 (-1.07;-0.19) - 0.58 (-1.13;-0.15)
Pain 17 28.4 (31) -17.6 (37.5) 0.07 - 0.47 (-0.90;-0.09) - 0.56 (-1.07;-0.05)
Nausea and vomiting 16 12.7 (22.5) -6.2 (21.8) 0.27 - 0.28 (-0.69;0.28) - 0.27 (-0.66;0.25)
    Single itemsf :       
Dyspnoea 16 21.6 (26.2) -8.3 (25.8) 0.22 - 0.32 (-1.05;0.65) - 0.31 (-0.89;0.17)
Sleep disturbance 16 45.1 (31) -12.5 (38.2) 0.21 - 0.32 (-0.86;0.19) - 0.40 (-0.98;0.38)
Appetite loss 16 29.4 (30.9) -12.5 (26.9) 0.08 - 0.46 (-0.93;0.01) - 0.40 (-0.87;0.08)
Diarrhoea 17 19.6 (23.7) +3.9 (33.1) 0.63 0.11 (-0.38;0.64) 0.16 (-0.41;1.17)
Constipation 17 17.6 (29.1) -5.9 (27.0) 0.38 - 0.21 (-0.75;0.31) - 0.20 (-0.67;0.31)
Financial impact 17 5.9 (17.6) +3.9 (11.1) 0.16 0.35 (0.11;0.57) 0.22 (-0.05;0.49)
EORTC QLQ-CR38:       
    Functional scalese:       
Body image 16 81.7 (28) +3.8 (14.2) 0.30 0.27 (-0.33;0.69) 0.13 (-0.13;0.37)
Future perspective 16 45.1 (28.7) +22.9 (31.5) 0.01 0.70 (0.27;1.27) 0.79 (0.27;1.38)
Sexual functioning 14 20.2 (20.9) +5.9 (16.8) 0.21 0.37 (-0.28;0.86) 0.28 (-0.15;0.83)
Sexual enjoyment 7 54.2 (43.4) +9.5 (41.8) 0.57 0.23 (-0.56;1.28) 0.21 (-0.73;0.91)
    Symptom scalesf :       
Radiation-induced effects micturition 16 23.5 (15.2) +4.8 (15.7) 0.23 0.30 (-0.23;0.91) 0.32 (-0.23;0.89)
Chemotherapy side effects 16 18.6 (19.5) +4.2 (18.4) 0.38 0.23 (-0.30;1.1) 0.21 (-0.77;0.92)
General Gastrointestinal symptoms 16 23.0 (12) -7.0 (14.3) 0.07 -0.49 (-1.38;0.11) - 0.58 (-1.45;0.17)
Defecation problems 13 15.4 (11.5) -1.8 (8.2) 0.43 -0.22 (-1.10;0.41) - 0.16 (-0.65;0.32)
Stoma-related problems 4 31.0 (21.5) -1.2 (13.7) 0.87 -0.10 (-1.15;1.02) - 0.05 (-1.96;2.43)
Sexual dysfunction of men 8 43.8 (41.7) -2.1 (35.0) 0.87 -0.06 (-1.43;0.82) - 0.04 (0.84;0.64)
Sexual dysfunction of women 2 8.3 (11.8) -8.3 (11.8) 0.50 -0.70 (-1.44;-0.31) -0.70 (-1.44;-0.31)
Weight loss 16 25.5 (34.4) -22.9 (33.8) 0.02 -0.67 (-1.01;-0.35) - 0.66 (-1.01;-0.36)
FACT-Ce:       
Physical Well-Being 17 78.0 (15.3) +5.3 (15.8) 0.18 0.34 (-0.20;0.85) 0.34 (-0.17;0.87)
Social/Family Well-Being 17 74.3 (21.1) +3.2 (18.3) 0.48 0.17 (0.47;0.59) 0.15 (-0.39;0.48)
Emotional Well-Being 17 74.3 (19.6) +3.3 (13.7) 0.34 0.24 (-0.32;0.64) 0.16 (-0.16;0.48)
Functional Well-Being 17 50.8 (17.1) +10.0 (13.2) 0.007 0.75 (0.20;1.27) 0.58 (0.19;0.93)
Colorectal Cancer Specific 16 69.6 (10.6) +3.9 (12.9) 0.25 0.30 (-0.26;0.88) 0.36 (-0.27;0.98)
FACT-C total score 17 69.5 (8.6) +1.6 (9.0) 0.49 0.19 (-0.36;0.71) 0.18 (-0.35;0.81)
Trial Outcome Index-Colorectal 17 66.4 (10.6) +4.7 (13.0) 0.152 0.36 (-0.20;0.96) 0.44 (-0.29;0.99)
  1. a Standard Deviation. b Wilcoxon test for the difference. c Standardized Response Mean. d Effect Size
  2. e Higher score indicates a higher level of functioning or better quality of life. f Higher score indicates more symptoms/problems. Bold indicate p values < 0.05.